Specialists address the intricate factors between comorbidities, efficacy, and tolerance, which influence their treatment approaches at the time of diagnosis. Mark Socinski, MD: Martin, we have seen ...

ECOG performance status is an important risk factor for early mortality in metastatic castration-resistant prostate cancer (mCRPC). Patients with metastatic castration-resistant prostate cancer (mCRPC ...

Patients with ECOG performance status of 1 reported worse global health status, quality of life, and physical functioning than those with a status of 0. The RATIONALE-305 trial showed Tevimbra plus ...

Performance status (PS) is a crucial assessment for research and clinical practice in lung cancer (LC), including its usage for the assessment of the suitability and toxicity of treatment or ...